Copyright © 2019. Inderes Oy. All rights reserved.
Search
User account

Hei!

Luo ilmainen tili jotta voit seurata yrityksiä, osallistua foorumin keskusteluun sekä kommentoida meidän sisältöä. Valitse sinulle sopivin tili.

Oliko sinulla jo tili?

Log in
Orion
5956 investors follow this company
BUY 39.53 LOWEST 39.44 VOLUME 300 645
SELL 39.56 HIGHEST 40.30 VALUE 11,934 Milj. EUR

Would you like to see our recommendations and target prices?

You already have an Inderes account? Log in from here.

Analyytikko

Petri Kajaani
+358 50 527 8680

Latest insider trading

Type: stock_exchange_release
2.12.
2019

Orion to present four posters on oral levosimendan in patients with ALS at the 30th International Symposium on ALS/MND

Orion Corporation                        Press release                               2 December 2019 at 1.00 p.m. EET

Type: stock_exchange_release
28.11.
2019

ORION CORPORATION STOCK EXCHANGE RELEASE 28 NOVEMBER 2019 at 10.20 EET             
         
Orion Corporation: Disclosure under chapter 9, section 10 of the Securities Market Act: The total share of voting rights of Orion shares owned by Maa- ja vesitekniikan tuki ry and a company controlled by it, Tukinvest Oy, has exceeded 5%

Type: stock_exchange_release
28.11.
2019

ORION CORPORATION STOCK EXCHANGE RELEASE 28 NOVEMBER 2019 at 9.30 EET             
         
192,172 Orion Corporation A shares converted into B shares

In accordance with Section 3 of the Articles of Association of Orion Corporation, 192,172 A shares have been converted into 192,172 B shares. The conversion has been entered into the Trade Register on 28 November 2019.

Type: stock_exchange_release
4.11.
2019

Orion Research Foundation grants 902 000 euros for research in 2020

Orion Research Foundation sr  Press release   4 November 2019

Orion Research Foundation sr is distributing EUR 902 000 in research grants based on applications for 2020. Orion Reaserch Foundation awards grants of max EUR 50,000 for 16 researchers for postdoctoral research and max EUR 5,000 for 65 young researchers for doctoral dissertation work.

Type: stock_exchange_release
4.11.
2019

ORION CORPORATION STOCK EXCHANGE RELEASE 4 NOVEMBER 2019 at 9.00 EET             
         
125,000 Orion Corporation A shares converted into B shares

In accordance with Section 3 of the Articles of Association of Orion Corporation, 125,000 A shares have been converted into 125,000 B shares. The conversion has been entered into the Trade Register on 4 November 2019.

Type: stock_exchange_release
28.10.
2019

ORION CORPORATION     STOCK EXCHANGE RELEASE   28 OCTOBER 2019 at 19.30 EET

Composition of the Nomination Committee of Orion Corporation

The Board of Directors of Orion Corporation has elected the following persons to the Nomination Committee of the company:

Type: stock_exchange_release
23.10.
2019

ORION CORPORATION     INTERIM REPORT 1-9/2019    JANUARY–SEPTEMBER 2019  
23 October 2019 at 12.00 EEST

 

Orion Group Interim Report 1–9/2019

Net sales in January–September 2019 totalled EUR 776 million
(EUR 715 million in January–September 2018).

Type: stock_exchange_release
7.10.
2019

ORION CORPORATION PRESS RELEASE 7 OCTOBER 2019 at 09.00 EEST             
         
Publishing of Orion Corporation's Interim Report for January-September 2019 on 23 October 2019

Type: stock_exchange_release
2.9.
2019

ORION CORPORATION STOCK EXCHANGE RELEASE 2 SEPTEMBER 2019 at 9.30 EEST             
         
135,000 Orion Corporation A shares converted into B shares

In accordance with Section 3 of the Articles of Association of Orion Corporation, 135,000 A shares have been converted into 135,000 B shares. The conversion has been entered into the Trade Register on 2 September 2019.

Type: stock_exchange_release
7.8.
2019

ORION CORPORATION PRESS RELEASE 7 AUGUST 2019 at 10.30 am EEST             
         
Sales of darolutamide started in the USA – Orion receives EUR 45 million milestone

Orion

Orion lyhyesti

Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs.